BBIO three-lens brief
Evidence-based stock research on BBIO. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
Moved -4.71% yesterday. · Trading >3% below the 50-day MA — short-term weakness.
- Moved -4.71% yesterday.
- Trading >3% below the 50-day MA — short-term weakness.
- Underperforming SPY by 17.1pp over 30 days.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Analyst mean target $109.10 — 50% above current (21 analysts).
BBIO closed at $72.50 (-4.71%) as of 2026-09-11. Market cap: $14.17B. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $109.10 — 50% above current (21 analysts).. Concerns: moved -4.71% yesterday.; trading >3% below the 50-day MA — short-term weakness.. Last quarter: Revenue $243.68M, net income -$152.22M, free cash flow -$320.26M.
Why three lenses on BBIO, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BBIOacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/BBIO" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BBIO brief"></iframe>